Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Amortizatization of Intangibles (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Amortizatization of Intangibles for 11 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 123.21% year-over-year to $2.1 million, compared with a TTM value of $8.1 million through Dec 2025, changed N/A, and an annual FY2025 reading of $8.1 million, changed N/A over the prior year.
  • Amortizatization of Intangibles was $2.1 million for Q4 2025 at Spyre Therapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $3.6 million in Q2 2024 and bottomed at -$9.0 million in Q4 2024.
  • Average Amortizatization of Intangibles over 5 years is $539842.1, with a median of $164000.0 recorded in 2023.
  • The sharpest move saw Amortizatization of Intangibles plummeted 1700.0% in 2021, then skyrocketed 6258.93% in 2024.
  • Year by year, Amortizatization of Intangibles stood at -$58000.0 in 2021, then skyrocketed by 281.03% to $105000.0 in 2022, then soared by 1898.1% to $2.1 million in 2023, then crashed by 528.27% to -$9.0 million in 2024, then skyrocketed by 123.21% to $2.1 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for SYRE at $2.1 million in Q4 2025, $1.3 million in Q3 2025, and $2.0 million in Q2 2025.